These figures summarise how Cagrilintide is commonly described in research literature and supplier documentation, including the Cagrilintide listing at peptidesuk4u.co.uk
Image: IPGGutenbergUKLtd/Getty Images About the Author Julie Corliss, Executive Editor, Harvard Heart Letter About the Reviewer Eric G
8,9,30 The agents used in these trials, including higher-dose semaglutide (2.4 mg) and the dual GLP-1/GIP receptor agonist tirzepatide, have demonstrated compelling benefits
Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner
Key Point: Important Update: FDA Ruling on Compounded GLP-1s As of March 2025, the FDA has declared the shortages of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) to be resolved